Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Abnormal accumulation of β-amyloid (Aβ) in Alzheimer's disease (AD) is associated with prominent brain inflammation. Whereas earlier studies concluded that this inflammation is detrimental, more recent animal data suggest that at least some inflammatory processes may be beneficial and promote Aβ clearance. Consistent with these observations, overproduction of transforming growth factor (TGF)-β1 resulted in a vigorous microglial activation that was accompanied by at least a 50% reduction in Aβ accumulation in human amyloid precursor protein (hAPP) transgenic mice. In a search for inflammatory mediators associated with this reduced pathology, we found that brain levels of C3, the central component of complement and a key inflammatory protein activated in AD, were markedly higher in hAPP/TGF-β1 mice than in hAPP mice. To assess the importance of complement in the pathogenesis of AD-like disease in mice, we inhibited C3 activation by expressing soluble complement receptor-related protein y (sCrry), a complement inhibitor, in the brains of hAPP mice. Aβ deposition was 2- to 3-fold higher in 1-year-old hAPP/sCrry mice than in age-matched hAPP mice and was accompanied by a prominent accumulation of degenerating neurons. These results indicate that complement activation products can protect against Aβ-induced neurotoxicity and may reduce the accumulation or promote the clearance of amyloid and degenerating neurons. These findings provide evidence for a role of complement and innate immune responses in AD-like disease in mice and support the concept that certain inflammatory defense mechanisms in the brain may be beneficial in neurodegenerative disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“other studies have reported that inhibition of different components of complement impaired Aβ phagocytosis, resulting in elevated synapse loss.”
From Microglia in Alzheimer's disease (2017) · cites this paper as [122]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The deficiency of complement factors such as C1q, C3, C3ar1, C5aR, and Cd59, has exacerbated neuropathology in some studies [84–86] and reduced neuropathology in others [87–89].”
From Age, sex and Alzheimer’s disease: a longitudinal study of 3xTg-AD mice reveals sex-specific disease trajectories and inflammatory responses mirrored in postmortem brains from Alzheimer’s patients (2024) · cites this paper as [85]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In the same studies, complement blockade was associated with increased neurodegeneration.”
From Microglia in Alzheimer's disease (2017) · cites this paper as [122]
The cited source says what the claim attributes to it.
In the citing paper
“C3 inhibition enhanced plaque deposition and promoted neurodegeneration in J20 hAPP mice either by over-expression of sCrry (22) or genetic deletion of C3 (21).”
From Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice (2017) · cites this paper as [22]
The cited source says what the claim attributes to it.
In the citing paper
“Further, studies manipulating the complement system have yielded mixed results.”
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Self-citationImmunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Cellular Scaling Rules for the Brains of Marsupials: Not as “Primitive” as Expected
Dos Santos, S. E., Porfirio, J., da Cunha, F. B., Manger, P. R., Tavares, W., Pessoa, L., Raghanti, M. A., Sherwood, C. C., & Herculano-Houzel, S. (2017) · Brain, Behavior and Evolution · doi:10.1159/000452856 · Cited by 2,642
NeuN, a neuronal specific nuclear protein in vertebratesxs
Mullen, R. J., Buck, C. R., & Smith, A. M. (1992) · Development · doi:10.1242/dev.116.1.201 · Cited by 2,351
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856
Self-citationAβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C., Hardy, J., Duff, K., Jantzen, P., DiCarlo, G., Wilcock, D., et al. (2000) · Nature · doi:10.1038/35050116 · Cited by 1,498
Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies
Botto, M., Dell' Agnola, C., Bygrave, A. E., Thompson, E. M., Cook, H. T., Petry, F., Loos, M., Pandolfi, P. P., & Walport, M. J. (1998) · Nature Genetics · doi:10.1038/ng0598-56 · Cited by 1,434
Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431
Inflammation in Neurodegenerative Disease—A Double-Edged Sword
Wyss-Coray, T., & Mucke, L. (2002) · Neuron · doi:10.1016/s0896-6273(02)00794-8 · Cited by 1,235
Self-citation
Research works printed but not linked: 4
- Wyss-Coray, T. & Mucke, L. (2002) Neuron, in press. [DOI] [PubMed]
- Terry R. D., Masliah, E. & Hansen, L. A. (1994) in Alzheimer Disease, eds. Terry, R. D., Katzman, R. & Bick, K. L. (Raven, New York), pp. 179–196.
- Frautschy S. A., Cole, G. M. & Baird, A. (1992) Am. J. Pathol. 140, 1389-1399. [PMC free article] [PubMed] [Google Scholar]
- Holers V. M. (1996) in Clinical Immunology: Principles and Practice, ed. Rich, R. R. (Mosby, St. Louis), pp. 363–391.
Cited by
Items 301–400 of 466
Immunotherapy in Alzheimer's Disease: Where Do We Stand? Where Should We Go?
von Bernhardi, R. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1248 · Cited by 28
“Promotion of Aβ clearance appears to be associated with the activation of the complement system by Aβ-antibody complexes, a possibility that is supported by evidence obtained in complement-deficient mice [40].”
ResultBedoui, Y., Neal, J. W., & Gasque, P. (2018) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-018-9793-6 · Cited by 29
Zhang, X., Luhrs, K. J., Ryff, K. A., Malik, W., Driscoll, M., & Culver, B. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.03.010 · Cited by 29
van Luijn, M. M., van Meurs, M., Stoop, M. P., Verbraak, E., Wierenga‐Wolf, A. F., Melief, M., Kreft, K. L., Verdijk, R. M., Hart, B. A. ‘., Luider, T. M., et al. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlv004 · Cited by 28
“Age in years, mean (range) 63 (38-82) 63 (34-81) 65 (42-77) pH CSF, mean (range) 6.”
BackgroundInfluentialYi, Y., Chang, Y., Li, S., Zhu, J., Wu, Y., Jiang, X., Li, L., Liu, R., Ma, R., & Li, G. (2023) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2023.110685 · Cited by 28
Larkin, P. B., & Muchowski, P. J. (2012) · Journal of Huntington s Disease · doi:10.3233/jhd-2012-120021 · Cited by 27
“In AD and mouse models of AD, many complement components in the brain will bind to aggregated extracellular amyloid beta and indeed studies suggest that altering complement activity in AD brain alters removal of these plaques [46].”
BackgroundInflammation in Alzheimer’s disease
Heneka, M. T. (2006) · Clinical Neuroscience Research · doi:10.1016/j.cnr.2006.09.005 · Cited by 34
Processo Inflamatório e Neuroimunomodulação na Doença de Alzheimer
Rocha, N. P., Martins, L. D. C. A., Teixeira, A. L., & Reis, H. J. (2001) · Revista Neurociências · doi:10.34024/rnc.2011.v19.8385 · Cited by 28
Complement component 3 (C3) expression in the hippocampus after excitotoxic injury: role of C/EBPβ
Hernández-Encinas, E., Morante, D. A., Morales-Garcia, J. A., Giné, E., Sanz-SanCristóbal, M., Santos, Á., & Pérez‐Castillo, A. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0742-0 · Cited by 26
Gangliosides in Inflammation and Neurodegeneration
Furukawa, K., Ohmi, Y., Tajima, O., Ohkawa, Y., Kondo, Y., Ji, S., Hashimoto, N., & Furukawa, K. (2018) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2018.01.009 · Cited by 25
The Role of Complement in Stroke Therapy
Komotar, R. J., Kim, G. H., Otten, M. L., Hassid, B. G., Mocco, J., Sughrue, M. E., Starke, R. M., Mack, W. J., Ducruet, A. F., Merkow, M. B., et al. (2008) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-78952-1_2 · Cited by 26
“In another study, mice doubly transgenic for human amyloid precursor peptide (hAPP) and sCrry, experienced significantly more extensive Alzheimer’s-type neurodegeneration compared to mice only transgenic for hAPP ( Wyss-Coray et al. 2002 ).”
BackgroundFixemer, S., de la Maza, M. M., Hammer, G. P., Jeannelle, F., Schreiner, S., Gérardy, J., Boluda, S., Mirault, D., Mechawar, N., Mittelbronn, M. G. A., et al. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02857-8 · Cited by 26
“…Wyss-Coray et al. have shown that expression of soluble complement receptor-related protein y (sCrry), an inhibitor of C3 activation, in the APP/PS1 mouse model leads to a decrease in PaM activation, a 2–threefold increase in amyloid load and a higher accumulation of degenerating neurons [106].”
Mansour, G. K., Bolgova, O., Hajjar, A. W., & Mavrych, V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262411843 · Cited by 25
Novel Molecular Mechanisms of Gangliosides in the Nervous System Elucidated by Genetic Engineering
Furukawa, K., Ohmi, Y., Yesmin, F., Tajima, O., Kondo, Y., Zhang, P., Hashimoto, N., Ohkawa, Y., Bhuiyan, R. H., & Furukawa, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061906 · Cited by 24
“For example, roles during developmental processes [38] or neuronal generation in adults [39] have been reported.”
BackgroundThe Role of Complement Dysregulation in AMD Mouse Models
Ding, J., Kelly, U., Groelle, M., Christenbury, J. G., Zhang, W., & Rickman, C. B. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-3209-8_28 · Cited by 25
Role of the Retromer Complex in Neurodegenerative Diseases
Li, C., Shah, S. Z. A., Zhao, D., & Yang, L. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00042 · Cited by 22
“Several studies found that inhibition of microglial phagocytosis by defects in various receptors and proteins that participated in phagocytosis resulted in neurodegeneration and amyloidosis in mouse models of AD (Lu and Lemke, 2001; Wyss-Coray et al., 2002; Kaifu et al., 2003; Heneka et al., 2013).”
BackgroundA beneficial role for IL-1β in Alzheimer disease?
Lemere, C. A. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32356 · Cited by 25
Neuroinflammation and Alteration of the Blood-Brain Barrier in Alzheimer´s Disease
Soto-Rojas, L. O., de la Cruz‐López, F., Ontiveros‐Torres, M. Á., Viramontes‐Pintos, A., Cárdenas‐Aguayo, M. D. C., Meraz‐Ríos, M. A., Salinas‐Lara, C., Florán, B., & Luna‐Muñoz, J. (2015) · InTech eBooks · doi:10.5772/60024 · Cited by 23
“But inflammation can be neuroprotective in its early stages [46] and the inability to resolve the activating stimulus can result in a chronic inflammatory response.”
BackgroundKlimkowicz‐Mrowiec, A., Sado, M., Dziubek, A., Dziedzic, T., Pera, J., Szczudlik, A., & Słowik, A. (2013) · Neurologia i Neurochirurgia Polska · doi:10.5114/ninp.2013.33825 · Cited by 23
“The complement inhibition was shown to reduce the clearance of β-amyloid in animal models [11].”
BackgroundC1q Regulates Horizontal Cell Neurite Confinement in the Outer Retina
Burger, C. A., Jiang, D., Li, F., & Samuel, M. A. (2020) · Frontiers in Neural Circuits · doi:10.3389/fncir.2020.583391 · Cited by 20
“In the brain C1q may participate in the progression of diseases ranging from epilepsy to Alzheimer’s disease (Eikelenboom and Stam, 1982; Ishii and Haga, 1984; Afagh et al., 1996; Pasinetti, 1996; Wyss-Coray et al., 2002; Fonseca et al., 2004; Aronica et al., 2007; Ma et al., 2013).”
BackgroundComplement therapeutics in neurodegenerative diseases
Zelek, W. M., & Tenner, A. J. (2025) · Immunobiology · doi:10.1016/j.imbio.2025.153089 · Cited by 21
Neuroinflammation as a therapeutic target in neurodegenerative diseases
Gordon, R., & Woodruff, T. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805120-7.00003-8 · Cited by 25
Park, S. M., Shin, J. H., Moon, G. J., Cho, S. I., Lee, Y. B., & Gwag, B. J. (2011) · BMC Neuroscience · doi:10.1186/1471-2202-12-106 · Cited by 22
“Furthermore, overexpression of soluble complement receptor-related protein y, a complement inhibitor, reduces microglial activation, produces neurodegeneration, and enhances Ab production and accumulation in human amyloid precursor protein transgenic mice bearing the amyloidogenic K670M, N671L, and V717F mutations [39…”
Early complement activation increases in the brain in some aged normal subjects
Loeffler, D. A., Camp, D. M., Schonberger, M. B., Singer, D. J., & LeWitt, P. A. (2003) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.11.003 · Cited by 20
“In addition, expression of the endogenous complement inhibitor soluble CR1-related gene/protein y (sCrry) in human amyloid precursor protein (hAPP) transgenic mice results in increased A deposition and neuronal loss, suggesting a neuroprotective effect of complement activation in this animal model of AD [62].”
BackgroundInterferons: A molecular switch between damage and repair in ageing and Alzheimer’s disease
Gorlé, N., & Vandenbroucke, R. E. (2019) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2019.111148 · Cited by 22
Briggs, D. T., Martin, C. B., Ingersoll, S. A., Barnum, S. R., & Martin, B. K. (2007) · Glia · doi:10.1002/glia.20551 · Cited by 17
“Indeed, several studies have demonstrated a role for this protein in disease (Alexander et al., 2003; Davoust et al., 1999a; Rancan et al., 2003; Wyss-Coray et al., 2002).”
BackgroundUddin, M. S., Kabir, M. T., Mamun, A. A., Behl, T., Mansouri, R. A., Aloqbi, A. A., Perveen, A., Hafeez, A., & Ashraf, G. M. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200531151004 · Cited by 19
Digoxin Exhibits Neuroprotective Properties in a Rat Model of Dementia
Erdoğan, M. A., Kirazlar, M., Yiğittürk, G., & Erbaş, O. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03528-w · Cited by 20
Using animal models to determine the significance of complement activation in Alzheimer's disease.
Loeffler, D. A. (2004) · Journal of Neuroinflammation · doi:10.1186/1742-2094-1-18 · Cited by 21
Lana, D., Ugolini, F., & Giovannini, M. G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249441 · Cited by 17
Should development of Alzheimer¿s disease-specific intravenous immunoglobulin be considered?
Loeffler, D. A. (2014) · Journal of Neuroinflammation · doi:10.1186/s12974-014-0198-z · Cited by 18
“transgenic models of AD [116-120].”
Pillai, A., Bruno, D., Nierenberg, J. J., Pandya, C. D., Feng, T., Plaska, C. R., Ramos‐Cejudo, J., Osorio, R. S., Zetterberg, H., Blennow, K., et al. (2019) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2019.100007 · Cited by 16
“Contradictory to the above studies, a few complement proteins have been shown to provide protective effects such as decreasing neuropathology in rodent models of AD [23,25] or limiting neurodegeneration in injury models [42–44].”
ResultStahl, T., Reimers, C., Johne, R., Schliebs, R., & Seeger, J. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05069.x · Cited by 19
“Otherwise shared downstream events such as the activation of the complement system could be involved in the amyloid redistribution observed in both model systems (Dietzschold et al., 1995; Wyss-Coray et al., 2002).”
BackgroundImmunotherapy for Alzheimer's Disease
McGeer, P. L., & McGeer, E. G. (2004) · Science of Aging Knowledge Environment · doi:10.1126/sageke.2004.27.pe29 · Cited by 18
Kouki, M. A., Pritchard, A. B., Alder, J. E., & Crean, S. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215103 · Cited by 18
“This hypothesis focuses on the fact that pathogens such as herpes simplex viruses (HSV) have been found in the brains of AD patients [13], and that A (cid:2) accumulation may represent an anti-viral response, given some support by a recent study which reported that A (cid:2) 42 shares a similar…”
Immunotherapy for Alzheimer's disease
Wang, W., Fan, L., Xu, D.-E., Wen, Z., Yu, R., & Ma, Q. (2012) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gms065 · Cited by 19
The BCL-2 family protein Bid is critical for pro-inflammatory signaling in astrocytes
König, H., Coughlan, K. S., Kinsella, S. M., Breen, B. A., & Prehn, J. H. M. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.06.008 · Cited by 15
“On the other hand, neuroinflammatory processes may 14 also stimulate tissue regeneration and exert beneficial effects during neurodegeneration 15 (Morganti-Kossman et al., 1997; Wyss-Coray et al., 2002; Zhao et al., 2006; Lalancette-16 Hébert, 2007).”
Fighting fire with fire: The immune system might be key in our fight against Alzheimer’s disease
Dujardin, P., Vandenbroucke, R. E., & Hoecke, L. V. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.01.004 · Cited by 15
Latif‐Hernandez, A., Yang, T., Butler, R. R., Losada, P. M., Minhas, P. S., White, H., Tran, K. C., Liu, H., Simmons, D. A., Langness, V. F., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13857 · Cited by 14
Self-citationCentral Nervous System Diseases and Inflammation
Tenner, A. J., & Pisalyaput, K. (2007) · Springer eBooks · doi:10.1007/978-0-387-73894-9_8 · Cited by 15
Do Amyloid β-associated Factors Co-deposit with Aβ in Mouse Models for Alzheimer's Disease?
Timmer, N., Kuiperij, H. B., de Waal, R. M. W., & Verbeek, M. M. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100711 · Cited by 15
“Although the activated complement system can accelerate (A β -induced) neurodegeneration [83], there is also evidence that it can protect the brain from A β -induced damage [84].”
Latham, A. S., Rocha, S. M., McDermott, C. P., Reigan, P., Slayden, R. A., & Tjalkens, R. B. (2024) · NeuroToxicology · doi:10.1016/j.neuro.2024.06.017 · Cited by 12
Daskoulidou, N., Carpanini, S. M., Zelek, W. M., & Morgan, B. P. (2024) · Current topics in behavioral neurosciences · doi:10.1007/7854_2024_524 · Cited by 12
Byrne, R. A. J., Torvell, M., Daskoulidou, N., Fathalla, D., Kokkali, E., Carpanini, S. M., & Morgan, B. P. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02419-5 · Cited by 13
Nipecotic Acid Derivatives as Potent Agents against Neurodegeneration: A Preliminary Study
Papagiouvannis, G., Theodosis‐Nobelos, P., & Rekka, E. A. (2022) · Molecules · doi:10.3390/molecules27206984 · Cited by 12
“Acute inflammation is associated with neuroprotection, whereas chronic inflammation causes neurotoxicity through cytokines release and ROS production [11].”
BackgroundLawrence, L. H. (2011) · Frontiers in bioscience · doi:10.2741/3890 · Cited by 14
“Three independent reports found that deficiency of the early C components not only failed to protect in the AlzD mouse, but exacerbated progression (148-150), suggesting a protective action of C.”
BackgroundMicroglia in Alzheimer’s Disease: A Favorable Cellular Target to Ameliorate Alzheimer’s Pathogenesis
Sumsuzzman, D. M., Uddin, M. S., Kabir, M. T., Hasana, S., Perveen, A., Alanazi, I. S., Albadrani, G. M., Abdel‐Daim, M. M., & Ashraf, G. M. (2022) · Mediators of Inflammation · doi:10.1155/2022/6052932 · Cited by 12
“More interestingly, higher expression of C3 mRNA levels is linked with a depletion in Aβ deposition in hAPP/TGF-β1 transgenic mice [121].”
BackgroundImmunological Approaches for Amyloid-beta Clearance Toward Treatment for Alzheimer's Disease
Solomon, B. (2008) · Rejuvenation Research · doi:10.1089/rej.2008.0689 · Cited by 15
Ramadass, M., Ghebrehiwet, B., & Kew, R. R. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.10.022 · Cited by 12
“…precursor protein (hAPP) using soluble complement receptor-related protein y (sCrry, a murine complement inhibitor) leads to 2- to 3-fold higher Aβ deposition in the brain and is accompanied by a prominent accumulation of degenerating neurons when complement is inhibited (Wyss-Coray et al., 2002).”
BackgroundThe Complement System: A Potential Target for Stroke Therapy
Mocco, J., Sughrue, M. E., Ducruet, A. F., Komotar, R. J., Sosunov, S. A., & Connolly, E. S. (2006) · Advances in experimental medicine and biology · doi:10.1007/0-387-34134-x_13 · Cited by 12
Lavrentaki, V., Kousaxidis, A., Theodosis‐Nobelos, P., Papagiouvannis, G., Koutsopoulos, K., & Nicolaou, I. (2023) · Molecular Diversity · doi:10.1007/s11030-023-10775-8 · Cited by 10
Banda, N. K., Tomlinson, S., Scheinman, R. I., Ho, N., Ramirez, J. R., Mehta, G., Wang, G., Vu, V. P., Simberg, D., Kulik, L. N., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.575154 · Cited by 9
“Crry has been shown play an important role in autoimmune disease such as lupus (MRL/lpr mice) (23, 24) and Alzheimer’s disease (25, 26).”
BackgroundFeng, B., Hu, P., Chen, J., Liu, Q., Li, X., & Du, Y. (2014) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317514537548 · Cited by 11
“In a word, CR1 played a protective role via the generation and binding of C3b, which might contribute to Ab clearance.(38) Therefore, we speculated that CR1 might play a role in AD via effecting on Ab.”
BackgroundFang, L., Tang, B.-S., Fan, K., Wan, C.-M., Yan, X., & Guo, J. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.04.042 · Cited by 10
Gabapentin Antioxidant Derivatives with Anti-Inflammatory and Neuroprotective Potency
Papagiouvannis, G., Theodosis‐Nobelos, P., Tziona, P., Gavalas, A. M., Kourounakis, P. N., & Rekka, E. A. (2021) · Letters in Drug Design & Discovery · doi:10.2174/1570180818666211210161922 · Cited by 10
The Role of the Immune System in Alzheimer's Disease
Cohen, R. M. (2009) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.7.1.foc28 · Cited by 10
Ma, S. L., & LAM, L. C. W. (2011) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2011.9.2.54 · Cited by 9
Shi, L., Winchester, L. M., Liu, B. Y., Killick, R., Ribé, E. M., Westwood, S., Baird, A. L., Buckley, N. J., Hong, S., Dobričić, V., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200208 · Cited by 8
“In some preclinical in vivo studies, C3 knock out offers synaptic protection and reduces amyloid burden in a range of models [43, 44], although in other studies increased amyloid accumulation and neurodegeneration has been reported [45, 46].”
BackgroundLutzenberger, M., Burwinkel, M., Riemer, C., Bode, V. G., & Baier, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134228 · Cited by 8
“A number of reports have linked complement component C3 to AD pathogenesis [42, 43].”
BackgroundDie Bedeutung der posttraumatischen Entzündungsreaktion im verletzten Gehirn
Schmidt, O. I., Leinhase, I., Hasenboehler, E. A., Morgan, S. J., & Stahel, P. F. (2007) · Der Orthopäde · doi:10.1007/s00132-007-1061-z · Cited by 12
Wang, J., Wu, J., Ma, X., Wu, Y., Xiao, Z., Zhou, X., Ding, D., & Zhao, Q. (2025) · Aging and Health Research · doi:10.1016/j.ahr.2025.100267 · Cited by 7
Singh, A. S., Naqvi, A. R., & Chanu, M. T. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2026.01.050 · Cited by 7
Innate immunity in the nervous system
Ramaglia, V., & Baas, F. (2009) · Progress in brain research · doi:10.1016/s0079-6123(09)17507-6 · Cited by 8
“May et al. (1990), Walker and McGeer (1992), Yasojima et al. (1999a, b) f. Zanjani et al. (2005) g. Gasque et al. (1997, 1998) h. McGeer and McGeer (2002) i. Fonseca et al. (2004) j. Wyss-Coray et al. (2002) Huntington’s disease a. Antibody-independent C activation on neurons in the caudate area b.”
BackgroundThe underestimated potential of the immune system in prevention of Alzheimer's disease pathology
Mohajeri, M. H. (2007) · BioEssays · doi:10.1002/bies.20630 · Cited by 8
Microglial Drivers of Alzheimer's Disease Pathology: An Evolution of Diverse Participating States
Kuhn, M. K., & Proctor, E. A. (2024) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26723 · Cited by 5
Zheng, Y., Ma, L., Wang, Y., Huang, J., Ye, J., & Yang, X. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c02188 · Cited by 5
Donev, R., & Howell, O. W. (2012) · Advances in protein chemistry and structural biology · doi:10.1016/b978-0-12-394287-6.00004-5 · Cited by 5
Microglia: Neuroprotective and Neurodestructive Properties
Harry, G. J., & McPherson, C. A. (2014) · Springer eBooks · doi:10.1007/978-1-4614-5836-4_55 · Cited by 6
Zhang, Q., Lo, H., Song, Y., Feng, L., You, H., Chen, X., Wang, Y., & Pan, X. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03598-8 · Cited by 4
“Another complement activation fragment of C3 is strongly correlated with the pathology of AD, which can be ameliorated via the inhibition of complement C3 [49], suggesting that C3 may potentially mitigate neuropathology in mouse models with mutant APP.”
Batista, A. F., Presumey, J., Singh, B. B., Yalçın, E., Schroeder, M. K., Khan, K., Spooner, E., Li, S. A., Carroll, M. C., & Lemere, C. A. (2025) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-025-00010-z · Cited by 4
“In 2002, Wyss-Corey and colleagues [70] reported that expression of soluble complement receptor-related protein y (sCrry) in J20 mice led to increased Aβ deposition (similar to [14, 27 and here]) which unlike the current study, was associated with ~ 50% loss of Neu-N positive neurons in hippocampal…”
Zhao, B., Zang, P., Quan, M., Wang, Q., Guo, D., Jia, J., & Wang, W. (2025) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70202 · Cited by 4
Innate Immune Mechanisms in the Central Nervous System
Shastri, A., Yasmin, H., & Kishore, U. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-85340-1_15 · Cited by 4
Doshmanziari, M., Sarveazad, A., Moradi, F., Shariatpanahi, M., Doshmanziari, E., Simorgh, S., & Eftekharzadeh, M. (2019) · Thrita · doi:10.5812/thrita.88367 · Cited by 6
“Aβ (1-42), DMEM, DiI, Thioflavin-S and DAPI stains were supplied from Sigma (St.”
BackgroundMethodLv, J., Yao, L., Tang, L., Li, Q., Wang, L., Yan, X., Li, M., Peng, W., Zhang, H., Guo, J., et al. (2026) · British Journal of Anaesthesia · doi:10.1016/j.bja.2026.02.024 · Cited by 3
Adaptive and Maladaptive Complement Activation in the Retina
Silverman, S. M., & Wong, W. T. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-27378-1_6 · Cited by 4
Fields, J. A., Swinton, M. K., Sundermann, E. E., Scrivens, N., Vallee, K.-A. J., & Moore, D. J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.981937 · Cited by 3
“However, other studies show that C3 mediates clearance of Aβ plaques (Wyss-Coray et al., 2002; Maier et al., 2008).”
BackgroundRobert, J., Cheng, W. H., Hayat, A., Ward-Able, T., & Wellington, C. L. (2015) · Clinical Lipidology · doi:10.2217/clp.14.64 · Cited by 5
Weggen, S., Czirr, E., Leuchtenberger, S., & Eriksen, J. L. (2007) · Springer eBooks · doi:10.1007/978-0-387-71522-3_11 · Cited by 4
Vegh, C., Walach, G., Dube, K., Dobson, B., Talukdar, R., Wear, D., Jayawardena, H., Dufault, K., Culmone, L., Srikantha, S., et al. (2025) · Nutrients · doi:10.3390/nu17162701 · Cited by 2
Suo, Y., Fu, Y., Wang, C., Wu, Y., & Tian, P. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111562 · Cited by 2
Roles of Innate Immunity and Inflammation in the Aging Brain
Okun, E., Chen, X., Bašta, M., & Mattson, M. P. (2011) · Oxidative stress and disease · doi:10.1201/b11014-2 · Cited by 2
Kustra, R., Awh, C. C., Rojas‐Fernandez, C. H., & Zanke, B. W. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180673 · Cited by 2
Development of early biomarkers of Alzheimer's disease: A precision medicine perspective
Sarkar, S., Das, N., & Sambamurti, K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824010-6.00006-x · Cited by 2
12th International Conference on Alzheimer's Disease (ICAD), Vienna, Austria
Strobel, G. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1250 · Cited by 2
“Mouse data, as well, connect complement activation with amyloid deposition [13,14].”
Biological Transgenic Mouse Models of Alzheimer's Disease
Crews, L. A., Rockenstein, E. M., & Masliah, E. (2008) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)01227-4 · Cited by 2
“To investigate this possibility and to assess the importance of complement in the pathogenesis of neurodegeneration in AD models, recent tg models have been developed where APP tg mice were crossed with tg mice to inhibit C3 complement activation (Wyss-Coray et al., 2002) (Table 27.2).”
BackgroundSelf-citationMorelli, L., Perry, G. L., & Tagliavini, F. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/709613 · Cited by 3
Boyd, T. D. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.05.1962 · Cited by 2
“Evidence supporting the innate immune system’s role in AD pathogenesis show that complement proteins are upregulated in AD brain, and that inhibition of C3 convertase significantly increases amyloid pathology in AD mice [26].”
BackgroundReitz, C., & Tosto, G. (2013) · Journal of Molecular and Genetic Medicine · doi:10.4172/1747-0862.1000060 · Cited by 2
The Role of Sex Steroids in Alzheimer's Disease: Prevention and Treatment
Henderson, V. W. (2007) · Elsevier eBooks · doi:10.1016/b978-012369443-0/50029-6 · Cited by 2
Li, T., Liu, B., Zeng, B., Yin, H., Sun, L., Liu, L., Li, P., & Li, Z.-H. (2026) · Environmental Science & Technology · doi:10.1021/acs.est.6c01442 · Cited by 1
Woodard, G. E. (2026) · Neurochemistry International · doi:10.1016/j.neuint.2026.106161 · Cited by 1
Multiple Sclerosis, Alzheimer’s Disease, and Inflammation: A Hypothetical View
Bynoe, M. S., & Viret, C. (2012) · Molecular and integrative toxicology · doi:10.1007/978-1-61779-812-2_9 · Cited by 1
Complement Component (3b/4b) Receptor 1 (CR1)
Lord, J., & Morgan, K. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7309-1_5 · Cited by 2
Significance of Complement Activation in Alzheimer’s Disease
Loeffler, D. A. (2008) · touchREVIEWS in Neurology · doi:10.17925/usn.2008.04.02.52 · Cited by 1
“Indeed, this process was generally accepted to play a deleterious role in AD until the publication in 2002 of a study by Wyss-Coray, et al.27 An animal model of AD, the transgenic APP mouse, was crossed with mice expressing soluble complement receptor-related protein y (sCrry), a rodent-specific Cognitive Aging Alzhei…”
BackgroundIs Alzheimer's Associated Amyloid Beta an Innate Immune Protein
Kandel, R., White, M. R., Hseih, I.-N., & Hartshorn, K. L. (2016) · InTech eBooks · doi:10.5772/63021 · Cited by 1
“However, it has been found that C3 deficiency or inhibition of complement worsens Aβ accumulation and neurodegeneration in mice [32].”
BackgroundNeuroinflammation in Alzheimer's Disease Continuum
Sag, A. T., & Yemişçi, M. (2020) · Neurological Sciences and Neurophysiology · doi:10.4103/nsn.nsn_190_20 · Cited by 1
Genetically Engineered Mouse Models of Neurodegenerative Disorders
Masliah, E., & Crews, L. A. (2007) · Springer eBooks · doi:10.1007/0-387-25919-8_19 · Cited by 1
Self-citationInnate and adaptive glial cell responses in Alzheimer’s disease
Singh, A., & Singh, T. R. (2023) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2023.00039 · Cited by 1
The Complement Cascade in Acute Brain Injury
McDowell, M. M., Shea, N. J., Gupta, G., & Connolly, E. S. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8915-3_5 · Cited by 1
The Involvement of Aβ in the Neuroinflammatory Response
Eikelenboom, P., van Gool, W. A., Rozemüller, A. J. M., Scheper, W., Veerhuis, R., & Hoozemans, J. J. M. (2006) · Springer eBooks · doi:10.1007/978-1-84628-440-3_4 · Cited by 2
“Inhibition of complement activation in the brain of hAPP mice by expressing soluble complement receptor-related protein (sCrry), a complement inhibitor, lead to a two- to threefold higher amyloid load and more neuronal loss than in agematched hAPP mice [152].”
Background
Metadata
- Authors
- Wyss-Coray, T., Yan, F., Lin, A. H.-T., Lambris, J. D., Alexander, J. J., Quigg, R. J., & Masliah, E.
- Affiliations
- Gladstone Institute of Neurological Disease and Department of Neurology, University of California, San Francisco, CA 94141; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104; Department of Medicine, Section of Nephrology, University of Chicago, Chicago, IL 60637; and Departments of Neurosciences and Pathology, University of California at San Diego, La Jolla, CA 92093
- University of California, San Francisco (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2002-07-15
- Volume
- 99
- Issue
- 16
- Pages
- 10837-10842
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC125059
- OpenAlex
- W2047658053
- Cited by
- 446
- References
- 47
- Citations by year
- 2026: 4 · 2025: 13 · 2024: 18 · 2023: 10 · 2022: 13 · 2021: 19 · 2020: 24 · 2019: 21 · 2018: 16 · 2017: 11 · 2016: 13 · 2015: 18 · 2014: 20 · 2013: 17 · 2012: 28
- FWCI
- 9.61
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (1r01ag015871-01a1, AG5131, n01ai30040-13-0-5, 5r29ag010869-05, AI-30040, AG10869, AG15871)
- National Institute on Aging (P50AG005131, AG-5131, AG10869, AG15871)
- National Institute of Allergy and Infectious Diseases (AI30040, N01 AI030040)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK41873, DK58820, R56DK041873, R01DK041873, U24DK058820)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Keywords
- Alzheimer's disease, complement activation, complement C3, amyloid-beta deposition, amyloid plaques, neurodegeneration, TGF-β1, microglial activation, innate immunity, amyloid precursor protein transgenic mice, neuroinflammation, amyloid clearance
- MeSH terms
- Alzheimer Disease, Animals, Brain, Complement Activation, Complement C3, Disease Models, Animal, Humans, Mice, Inbred C57BL, Mice, Transgenic, Nerve Degeneration, Neurons, Receptors, Complement, Gene Expression, Amyloid beta-Protein Precursor, Receptors, Complement 3b, Mice, Knockout, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.